This episode brings together four conversations on the topic of GLP-1 the science, the market data, the human impact, and the long-term strategic picture.
We hear from scientists, market strategists, clinicians and food innovators on what GLP-1 actually means for the food industry, and what it means for the people eating differently because of it.
Some market data suggests households on GLP-1 medications are spending 6% less on food overall. The consumer segment using these drugs in the UK is already roughly the same size as the vegan and vegetarian market.
How the food industry responds to this disruptive influence remains an open question, although serious moves are already being made.
